Daily Endocrinology Research Analysis
Three high-impact endocrinology studies stood out today: a double-blind RCT shows metformin blunts exercise-induced vascular insulin sensitivity; a randomized crossover trial finds isocaloric time-restricted eating shifts circadian phase but does not improve cardiometabolic health; and two nationwide cohort analyses link brighter daytime and dimmer nighttime light exposure and stable rest-activity rhythms with lower MASLD risk and progression.
Summary
Three high-impact endocrinology studies stood out today: a double-blind RCT shows metformin blunts exercise-induced vascular insulin sensitivity; a randomized crossover trial finds isocaloric time-restricted eating shifts circadian phase but does not improve cardiometabolic health; and two nationwide cohort analyses link brighter daytime and dimmer nighttime light exposure and stable rest-activity rhythms with lower MASLD risk and progression.
Research Themes
- Drug–exercise interactions in metabolic health
- Circadian timing versus isocaloric intake on cardiometabolic outcomes
- Light exposure and rest-activity rhythms in MASLD risk and progression
Selected Articles
1. Metformin Blunts Vascular Insulin Sensitivity After Exercise Training in Adults at Risk for Metabolic Syndrome.
In a 16-week double-blind RCT (n=91), metformin co-administered with low- or high-intensity exercise blunted improvements in insulin-stimulated conduit (FMD) and microvascular (MBF) function seen with exercise alone. Metformin also attenuated reductions in fasting glucose, endothelin-1, and TNF-α and prevented exercise-induced VO2max gains.
Impact: These data reveal a clinically relevant drug–exercise interaction that challenges assumptions that metformin uniformly augments cardiovascular benefits of exercise training.
Clinical Implications: When prescribing exercise for patients on metformin, clinicians should consider potential attenuation of vascular benefits and personalize timing/titration. Alternative glucose-lowering agents or staged initiation around training phases may be considered for patients prioritizing vascular adaptations.
Key Findings
- Metformin blunted exercise-induced increases in insulin-stimulated flow-mediated dilation (FMD) and microvascular blood flow (MBF) versus placebo arms (P < .05).
- VO2max improved with exercise + placebo but not with exercise + metformin.
- Metformin attenuated exercise-related reductions in fasting glucose, endothelin-1, and TNF-α.
Methodological Strengths
- Double-blind, placebo-controlled randomized design with intensity-stratified exercise arms
- Gold-standard euglycemic clamp with vascular phenotyping (FMD, CEUS-derived microvascular metrics)
Limitations
- Single-center trial with modest sample size
- Surrogate vascular endpoints; no hard cardiovascular outcomes
Future Directions: Test timing strategies (e.g., metformin dosing separated from training), compare alternative agents, and evaluate clinical cardiovascular outcomes in larger multicenter RCTs.
CONTEXT: Metformin is the first-line pharmacotherapy for treating hyperglycemia, and it lowers cardiovascular disease risk. Prior work suggests that metformin can, however, interfere with metabolic adaptations to exercise. To date, no work has tested if metformin (Met) alters exercise training mediated vascular insulin sensitivity, and whether this is exercise intensity dependent. OBJECTIVE: This work aimed to test the hypothesis that Met blunts vascular insulin sensitivity in an intensity-based manner among adults at risk for metabolic syndrome. METHODS: In a double-blind, placebo-controlled trial, participants were randomly assigned to low-intensity exercise plus placebo (∼55% VO2max 5d/wk, LoEx + PL, n = 22) or metformin (2000 mg/d, LoEx + Met, n = 21) and high-intensity exercise plus placebo (∼85% VO2max 5d/wk, HiEx + PL, n = 24) or metformin (HiEx + Met, n = 24) for 16 weeks. A 120-minute euglycemic-hyperinsulinemic clamp (40 mU/m2/min, 90 mg/dL) was conducted pre and post treatment to assess macrovascular insulin sensitivity via brachial artery flow-mediated dilation (%FMD, conduit artery) as well as microvascular insulin sensitivity using contrast-enhanced ultrasound (eg, microvascular blood volume [MBV, perfusion] and microvascular blood flow [MBF]). Fasting and clamp-derived glucose, insulin, inflammatory measures (eg, endothelin-1 [ET-1], tumor necrosis factor α [TNF-α], soluble receptor for advanced glycation end products [sRAGE]), and nitric oxide (nitrite/nitrate) were assessed. Aerobic fitness (maximal oxygen consumption [VO2max]) and body composition (dual-energy x-ray absorptiometry [DXA]) were also analyzed. RESULTS: LoEx + PL and HiEx + PL increased VO2max (both P < .05), while there was no change after LoEx + Met or HiEx + Met. Body fat was reduced following HiEx + PL and HiEx + Met only (both P < .05). Met blunted the increase in insulin-stimulated FMDallometric and MBF seen with LoEx + PL and HiEx + PL (P < .05). Met also attenuated the reductions in fasting glucose, ET-1, and TNF-α compared with LoEx + PL and HiEx + PL (P < .05). CONCLUSION: Met blunts exercise training-mediated increases in vascular insulin sensitivity at the levels of conduit arteries and capillaries, in parallel with altered inflammation and glycemic benefits.
2. Intended isocaloric time-restricted eating shifts circadian clocks but does not improve cardiometabolic health in women with overweight.
In a randomized crossover trial of 31 women, two-week early- versus late-window, isocaloric TRE did not improve insulin sensitivity or cardiometabolic risk factors, although both schedules shifted internal circadian phase. Findings suggest that timing alone without energy deficit may be insufficient for short-term cardiometabolic gains.
Impact: This high-quality negative trial clarifies that in the absence of caloric reduction, TRE’s timing does not confer short-term cardiometabolic benefits, refining guidance for dietary interventions.
Clinical Implications: Counsel patients that TRE without caloric deficit is unlikely to improve insulin sensitivity over weeks. Emphasize overall energy balance and sustainability; align eating windows with sleep/circadian preferences for adherence rather than expecting cardiometabolic benefits per se.
Key Findings
- Isocaloric early (08:00–16:00) vs late (13:00–21:00) TRE for 2 weeks did not change insulin sensitivity between conditions (effect ~ -0.07; 95% CI -0.77 to 0.62).
- Both TRE schedules shifted internal circadian phase, indicating biological clock entrainment without cardiometabolic improvement.
- Participants maintained habitual diet quality and quantity within the 8-hour window, isolating timing effects from caloric changes.
Methodological Strengths
- Randomized crossover design controlling for between-subject variability
- Isocaloric instruction isolates timing from caloric restriction effects
Limitations
- Short intervention periods (2 weeks per condition) may miss longer-term effects
- Female-only cohort limits generalizability to men
Future Directions: Evaluate longer TRE durations and weight-loss settings, include diverse populations, and integrate circadian biomarkers with continuous cardiometabolic monitoring.
Time-restricted eating (TRE) is a promising strategy to improve metabolic outcomes. However, it remains unclear whether TRE has cardiometabolic benefits in an isocaloric setting and whether its effects depend on the eating timing. We conducted a randomized crossover trial in 31 women with overweight or obesity to directly compare the effects of a 2-week early TRE (eTRE; eating from 8:00 to 16:00) and a 2-week late TRE (lTRE; eating from 13:00 to 21:00) on insulin sensitivity, cardiometabolic risk factors, and the internal circadian phase. During the restricted 8-hour eating period, participants were asked to consume their habitual food quality and quantity. Insulin sensitivity did not differ between (-0.07; 95% CI, -0.77 to 0.62;
3. Diurnal Light Exposure and Rest-Activity Rhythms in Relation to MASLD: Insights from Two Nationwide Cohort Studies.
Across UK Biobank (prospective) and NHANES, objective accelerometry and light data show that higher daytime light (>6000 lux), lower night-time light (>30 lux), and robust rest-activity rhythms (high RA, M10; low L5; earlier L5 onset) associate with reduced MASLD risk, less fibrosis/cirrhosis, and better survival among MASLD participants.
Impact: This large-scale, device-measured, bidataset analysis links modifiable light exposures and behavioral rhythms to MASLD incidence and progression, identifying pragmatic prevention targets.
Clinical Implications: Advise MASLD patients to increase daytime bright light exposure, minimize nocturnal light, and stabilize sleep–wake/activity schedules as adjuncts to metabolic care. Consider integrating light hygiene into lifestyle prescriptions and MASLD risk stratification.
Key Findings
- Each 0.1-unit increase in relative amplitude (RA) was linked to ~30% lower MASLD risk; higher M10 reduced risk, while higher L5 and delayed L5 onset increased risk.
- Each additional hour of daylight >6000 lux lowered MASLD risk by 9%; each additional 30 minutes of night light >30 lux raised risk by 22%.
- Favorable 24h rest-activity profiles and adequate light exposure associated with lower fibrosis/cirrhosis risk and improved life expectancy among MASLD participants; replicated in NHANES.
Methodological Strengths
- Objective accelerometry-based light and activity metrics across two nationwide cohorts
- Prospective analysis in UK Biobank with replication in NHANES
Limitations
- Observational design cannot establish causality; residual confounding possible
- MASLD diagnosis and fibrosis staging in cohorts may rely on algorithms/surrogates
Future Directions: Randomized light intervention trials in MASLD, mechanistic studies on circadian-metabolic coupling, and integration of light hygiene in MASLD care pathways.
BACKGROUND: Circadian rhythms may influence metabolic dysfunction-associated steatotic liver disease (MASLD), but the impact of personal light exposure and rest-activity rhythms on MASLD risk remain unclear. METHODS: The study utilized accelerometry data from both NHANES and UK Biobank cohorts. 24-hour rest-activity rhythm (24h-RAR) was assessed using nonparametric metrics, including activity level during the most active 10 hours (M10), activity level during the least active 5 hours (L5), relative amplitude (RA), M10 onset, and L5 onset. Light exposure was categorized into daytime and nighttime periods, with exposure durations recorded separately at different threshold levels. The primary outcome was MASLD, with secondary outcomes, including fibrosis and cirrhosis. RESULTS: In the UK Biobank prospective analysis, each 0.1-unit and 1-unit increase in RA and M10 were associated with a 30% and 2% reduction of MASLD risk, respectively. In contrast, each 1-unit increase in L5 and delayed L5 onset were linked to an 8% and 21% increase of MASLD risk. Moreover, each additional hour of daylight exposure above 6000 lux was associated with 9% lower risk of MASLD, while each additional 30 minutes of nightlight exposure above 30 lux corresponded to a 22% higher risk of MASLD. Additionally, a favorable 24h-RAR profiles and adequate light exposure were associated with a lower risk of fibrosis and cirrhosis, as well as improved life expectancy among participants with MASLD. Similar associations were observed in the NHANES analysis. CONCLUSION: Greater daytime light exposure, reduced nocturnal light exposure, and regulated rest-activity rhythms may protect against MASLD and prevent its progression to liver fibrosis and advanced liver disease.